Skip to main content

Table 2 Patient demographics and sample information

From: Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

  Group A (N = 14) Group B (N = 67) Total (N = 81)
Type of specimen Frozen plasma Fresh whole blood All samples
Age: median (range) 68 (44–73) 67 (45–93) 67 (44–93)
Gender: female N (%) 9 (64%) 46 (69%) 55 (68%)
Race/ethnicity: N (%)
 Caucasian 8 (57%) 43 (64%) 51 (63%)
 Asian 2 (14%) 13 (19%) 15 (19%)
 Hispanic 2 (14%) 6 (9%) 8 (10%)
 African American 2 (14%) 5 (7%) 7 (9%)
Cancer type/histology: N (%)
 LUAD 2 (14%) 40 (60%) 42 (52%)
 LUSC 9 (64%) 8 (12%) 17 (21%)
 Breast 3 (21%) 13 (19%) 16 (20%)
 Other cancer types* 0 6 (9%) 6 (7%)
  1. *Other cancer types include lung small cell carcinoma (n = 2); lung large cell neuroendocrine (n = 1); ovarian, adenocarcinoma (n = 2); prostate, adenocarcinoma (n = 1)
  2. LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma